Related Experiment Video

Updated: Jun 20, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Selective RNAi-mediated inhibition of mutated c-kit

Irene Ruano1, Marta Izquierdo

  • 1Centro de Biología Molecular Severo Ochoa, CSIC /UAM, Universidad Autónoma de Madrid, Departamento de Biología Molecular, C/ Nicolás Cabrera, 1 Campus de Cantoblanco, Madrid, Spain.

Journal of Rnai and Gene Silencing : an International Journal of RNA and Gene Targeting Research
|September 23, 2009
PubMed

Insights

RNA interference targeting the proto-oncogene c-kit effectively inhibits mast cell leukemia (MCL) cell growth. This RNAi therapy shows promise as a novel antiproliferative agent for MCL, particularly for imatinib-resistant cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • The proto-oncogene c-kit is crucial for mast cell development and survival.
  • Gain-of-function mutations in c-kit are common in mast cell leukemia (MCL).
  • Currently, no clinically approved treatments exist for MCL.

Purpose of the Study:

  • To investigate the potential of RNA interference (RNAi) against c-kit for treating human MCL.
  • To evaluate the efficacy of RNAi targeting wild-type and mutant c-kit in MCL cell lines.

Main Methods:

  • Retroviral transduction of HMC1.1 and HMC1.2 MCL cell lines.
  • Utilized vectors designed to transcribe RNAi against c-kit messenger RNA.
  • Assessed Kit protein levels, cell proliferation, and apoptosis post-infection.

Main Results:

  • Significant reduction in Kit protein levels observed in both cell lines.
  • Marked decrease in cell proliferation and increase in apoptosis within five days.
  • Demonstrated efficacy in HMC1.2 cells, which are resistant to imatinib mesylate.

Conclusions:

  • RNAi targeting c-kit or its mutant form is a potential antiproliferative strategy for human MCL.
  • This approach offers a promising therapeutic avenue, especially for imatinib-resistant MCL.
  • Further development of RNAi-based therapies for MCL is warranted.
Keywords:
RNAiallelic discriminationapoptosisc-kitmast cell leukemia (MCL)

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...